GlobeNewswire

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

Share
  • Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase 1 (SOD1) mutation
  • Late breaking interim data to be presented at the American Academy of Neurology Annual Meeting (AAN) show a statistically significant reduction in SOD1 protein levels and a numerical trend towards slowing of clinical decline in SOD1-ALS patients treated with tofersen
  • Biogen recently initiated VALOR, a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today interim results of a phase 1/2 study of tofersen, an antisense oligonucleotide (ASO) being studied for the potential treatment of amyotrophic lateral sclerosis (ALS) in adults with a confirmed superoxide dismutase 1 (SOD1) mutation. The data will be presented at the American Academy of Neurology Annual Meeting (AAN) in Philadelphia, PA (May 4-10, 2019).

“The interim results of this study, which achieved proof-of-biology and proof-of-concept, support the initiation of a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients and further demonstrate the potential of ASOs to target the genetic driver of disease,” said Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen. “We are committed to bringing a potential breakthrough therapy to patients with ALS and we are expediting our efforts with the aim of addressing this urgent unmet need.”

The Phase 1/2 study of tofersen in SOD1-ALS is a randomized, placebo-controlled, single- and multiple-ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy endpoints of tofersen in 70 patients with ALS. In the multiple ascending dose portion of the study, 50 participants with SOD1 mutations were randomized to receive tofersen (20 mg, 40 mg, 60 mg, or 100 mg) or placebo for 12 weeks.

In the interim analysis, treatment with tofersen 100 mg (n=10) over a three-month period resulted in a statistically significant lowering of SOD1 protein levels in the cerebrospinal fluid (p=0.002) and a numerical trend towards slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), slow vital capacity and muscle strength compared to placebo (n=12). Specifically, the mean change in ALSFRS-R score from baseline to Day 85 was -1.1 in the tofersen 100 mg group compared to -5.3 in the placebo group, on a 48-point scale. Across clinical measures, separation from the placebo group was most apparent in patients with fast progressing disease. The safety and tolerability profile in this analysis supports continued development of tofersen in ALS. The data will be presented by study co-principal investigator Timothy M. Miller, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, MO on May 7, 2019 at 11:45 a.m. ET as a late breaking oral presentation.

“ALS is a devastating disease and there are currently no therapeutic options that reliably slow or halt its rapid progression,” said Merit Cudkowicz, M.D., co-principal investigator and the director of the Healey Center at Massachusetts General Hospital. “We are encouraged by the positive results of this phase 1/2 study of tofersen in patients with SOD1-ALS and are excited to advance this clinical program to a phase 3 trial to further investigate its therapeutic potential.”

In March 2019 the first patient was dosed in the Phase 3 VALOR study of tofersen in adults with ALS with a confirmed SOD1 mutation. The VALOR study aims to assess the efficacy and safety of tofersen versus placebo. The primary endpoint of this study is an analysis based on the ALSFRS-R score, which is a validated rating instrument that monitors the progression of disability in patients with ALS. Biogen is collaborating with regulators to further define the scope of the clinical data package required to support the registration of tofersen.

ALS is a rare and fatal neurodegenerative disease characterized by motor neuron loss in the brain and spinal cord that is responsible for controlling voluntary muscle movement. Symptoms may vary depending on the location of the motor neuron failure and may include limb weakness, difficulty breathing and trouble speaking and swallowing. There is a growing body of evidence that mutations within multiple genes are believed to cause ALS. ALS with SOD1 mutations is a rare subtype of familial ALS and accounts for approximately two percent of all ALS cases.

About tofersen
Tofersen is an antisense oligonucleotide (ASO) being developed for the treatment of ALS with SOD1 mutations. Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H and reduction of SOD1 protein production. This is thought to decrease the toxicity of mutant SOD1 and potentially provide therapeutic benefit through improved survival and function to people with ALS with SOD1 mutations. Tofersen demonstrated proof-of-biology and proof-of-concept in a Phase 1/2 study. Biogen licensed tofersen from Ionis Pharmaceuticals, Inc. under a collaborative development and license agreement.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor Statement
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about results from the Phase 1/2 study of tofersen; the potential clinical effects of tofersen; the potential benefits, safety and efficacy of tofersen; the clinical development program for tofersen; the potential of our commercial business and pipeline programs, including tofersen; the anticipated benefits and potential of our collaboration arrangements with Ionis; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of tofersen; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including tofersen; the occurrence of adverse safety events; the risks of other unexpected hurdles, costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release.

We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

MEDIA CONTACT:

David Caouette  
+1 617 679 4945
public.affairs@biogen.com 
INVESTOR CONTACT:

Mike Hencke
+1 781 464 4471
IR@biogen.com 

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

DIAC S.A.: UPDATE OF NEU MTN PROGRAMME3.7.2020 19:32:13 CESTPress release

July, 3rd 2020 DIAC S.A.: UPDATE OF NEU MTN PROGRAMME DIAC S.A. updated the Information Memorandum of its Negotiable Medium Term Notes (NEU MTN Programme). This documentation was approved by the Banque de France is available on its website under the following link: https://eucpmtn.banque-france.fr/public/#/liste-des-emetteurs/5f8b9dec-b611-ea11-80f7-001dd8b71ea9 DIAC S.A. Etablissement de crédit et intermédiaire d’assurances, au capital de 659 334 050 EUR. Siège social : 14, avenue du Pavé Neuf – 93168 Noisy-le-Grand cedex SIREN 702 002 221 RCS Bobigny – N° TVA : FR02 702002221 – Code APE 6492Z – N° ORIAS : 07 004 966 – www.orias.fr Attachment Update DIAC programme NEU MTN 2020

Maha Energy AB (publ) Announce June Production Volumes3.7.2020 17:13:36 CESTPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm July 3, 2020 Maha Energy AB (publ) Announce June Production Volumes Production Volumes The Company's aggregate sales production for the month of June totaled 112,1511 barrels of oil and 57.090 million scf of gas for a combined average production of approximately 4,056 BOE/day2, before royalties and taxes. Other than some minor unplanned shutdowns, production continues to be affected by the impact of the Covid-19 pandemic. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is used. For more information, please contact: Jonas Lindvall (CEO) Tel: +46 8 611 05 11 Email: jonas@mahaenergy.ca or Victoria Berg (Investor Relations) Tel: +46 8 611 05 11 Email: victoria@mahaenergy.ca Maha in Brief Maha Energy AB is a Swedish public limited liability company. FNCA Sweden AB has been engaged as C

Norsk Hydro: Produksjon gjennopptatt ved Paragominas og Alunorte3.7.2020 17:00:00 CESTPressemelding

Strømtilførselen til Hydros bauksittgruve Paragominas i Parà nord i Brasil har blitt gjenopprettet og produksjonen har startet opp igjen. Produksjonen ved Hydros aluminaraffineri Alunorte vil som følge av dette også bli normalisert. Tre høyspentmaster veltet 20. juni og førte til strømbrudd for Paragominas. Strømbruddet stanset midlertidig produksjonen ved gruven. Høyspentmastene har nå blitt reparert og strømtilførelsen er gjenopprettet. Det var ingen personskader, miljøskader eller skader på produksjonsutstyr relatert til strømbruddet. Hydro samarbeider med lokale myndigheter for å finne årsaken til hendelsen. Foreløpige undersøkelser tyder på at deler fra mastene har blitt stjålet og at dette forårsaket at mastene veltet. Investorkontakt: Line Haugetraa +47 41406376 Line.Haugetraa@hydro.com Pressekontakt: Anders Vindegg +47 93864271 Anders.Vindegg@hydro.com

Norsk Hydro: Production resumed at Paragominas and Alunorte3.7.2020 17:00:00 CESTPress release

The power supply to Hydro’s Paragominas bauxite mine, in the state of Pará in northern Brazil, has been restored, allowing production to restart. As a result, production is being ramped up at Hydro’s Alunorte alumina refinery. On June 20, three power transmission towers overturned, cutting the power supply to the mine and temporarily halting production. The transmission towers have been repaired, and the power has been restored. There were no personnel injuries, damage to other production assets or impact on the nearby environment related to the power outage. The company is cooperating with local authorities to determine the cause of the incident. Preliminary findings indicate that parts were stolen from the towers causing them to overturn. Investor contact: Line Haugetraa +47 41406376 Line.Haugetraa@hydro.com Media contact: Anders Vindegg +47 93864271 Anders.Vindegg@hydro.com

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS3.7.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-07-07 Maturity dateLoanISIN codeCouponVolume, SEK million2021-09-15 2109 SE00069950641.00 %500+/- 2502024-10-022410 SE0010469205 1.00 %500+/- 250 Settlement date 2020-07-09 Bids have to be entered by 11.00 on JUL 07, 2020 Highest permitted bid volume: A maximum of SEK 500 million per bid in issue 2109 and 2410. Lowest permitted bid volume: 50 SEK million per bid Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON JUL 07, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK COVERED BONDS3.7.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-07-09 Maturity dateLoanISIN codeCouponVolume, SEK million2025-09-17 5535 SE0013358413 1.00 %1,000 +/- 5002024-12-18 579 SE00121936211.00 %1,000 +/- 500 2024-12-031589SE00116433861.50 %1,000 +/- 5002025-06-18195SE00135460661.00 %1,000 +/- 5002024-12-182412SE00126218521.00 %400 +/- 2502025-09-17518SE0011309244 1.25 %400 +/- 2502025-06-11 146 SE0013381571 0.50 %400 +/- 250 Settlement date 2020-07-13 Bids have to be entered by 10.00 on JUL 09 2020 Highest permitted bid volume: 1,000 SEK million in issue 5535 1,000 SEK million in issue 579 1,000 SEK million in issue 1589 1,000 SEK million in issue 195 400 SEK million in issue 2412 400 SEK million in issue 518 400 SEK million in issue 146 Maximum volume: 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON JUL 09, 2020. For more information, pleas